Shandong Xinhua Pharmaceutical Company Limited
000756.SZ · SHZ
Market closed13.69-1.27 (-8.49%)
Key statistics
Previous close14.96
Open14.98
Day high14.98
Day low13.69
52-week high18.70
52-week low11.71
Market cap6.87B
Volume16.16M
Average volume11.54M
P/E ratio37.30
Forward P/E—
EPS0.37
Dividend yield+2.01%
Market context
Why it moved
Shares of 000756.SZ (Shandong Xinhua Pharmaceutical) fell sharply today, likely driven by broad sector selling pressure and negative market sentiment weighing on pharmaceutical stocks amid a high-volume selloff that pushed the price to its intraday low.
What is happening
Recent company-specific developments and publisher coverage.
富途牛牛 · July 10, 2026Shandong Xinhua Pharmaceutical Company Limited (00719.HK) received an increase of 1.376 million H-shares from E Fund Management Co., Ltd., valued at approximately HK$8.3756 million.marketscreener.com · June 26, 2026Shandong Xinhua Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2025, Payable on 31 July 2026 Mt Newswire · April 15, 2026Shandong Xinhua Pharma Gets China Nod to Register Bumetanide Injection Mt Newswire · March 24, 2026Xinhua Pharmaceutical Gets China Approval for Ibuprofen Pain Relief Granules Mt Newswire · March 4, 2026Xinhua Pharmaceutical Gets Registration Certificate for Two Drugs in China Mt Newswire · February 9, 2026Shandong Xinhua Pharmaceutical Terminates Equity Acquisition Talks With NovoSana Mt Newswire · December 23, 2025Xinhua Pharmaceutical Gets Registration Certificate for Influenza Drug in China Mt Newswire · November 28, 2025Shandong Xinhua Pharmaceutical Gets China Approval for Prednisolone Acetate Raw Material Mt Newswire · November 28, 2025Shandong Xinhua Pharmaceutical Gets China Supplementary Approval for Epinephrine Hydrochloride Injection; Shares Fall 3% Mt Newswire · November 27, 2025Xinhua Pharmaceutical Gets China Nod for Inflammatory Disease Drug-Related Marketing